Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Accelerator Invests in Four New Startups

NEW YORK (GenomeWeb) – Illumina has added four genomics startups to its accelerator program, marking its ninth funding round, the company said on Tuesday.

The startups are BioAmp Diagnostics, a precision diagnostics company based in Berkeley, California and focused on antibiotic resistance; Celldom, a North Carolina firm developing single-cell analysis technology; Juno Bio, which is based in the UK and developing vaginal microbiome technology for health and fertility; and TriAxia Health, which is based in Boston and developing a digital health platform to manage patients with rare disease.

As part of Illumina's six-month investment program, the companies have lab and office space at Illumina's San Francisco Bay Area facility, genomics and sequencing expertise, business coaching, and access to capital.

Illumina launched its accelerator program in 2014 and has so far invested in 34 companies.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.